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Abstract
Background: Patients with metastatic tumors to the brain have a very poor prognosis. Increased
metastatic potential has been associated with the fibrinolytic system. We investigated the role of
the fibrinolytic enzyme plasmin in tumor cell migration across brain endothelial cells and growth of
brain metastases in an experimental metastatic melanoma model.
Methods: Metastatic tumors to the brain were established by direct injection into the striatum or
by intracarotid injection of B16F10 mouse melanoma cells in C57Bl mice. The role of plasminogen
in the ability of human melanoma cells to cross a human blood-brain barrier model was studied on
a transwell system.
Results: Wild type mice treated with the plasmin inhibitor epsilon-aminocaproic acid (EACA) and
plg-/- mice developed smaller tumors and survived longer than untreated wild type mice. Tumors
metastasized to the brain of wild type mice treated with EACA and plg-/- less efficiently than in
untreated wild type mice. No difference was observed in the tumor growth in any of the three
groups of mice. Human melanoma cells were able to cross the human blood-brain barrier model
in a plasmin dependent manner.
Conclusion: Plasmin facilitates the development of tumor metastasis to the brain. Inhibition of the
fibrinolytic system could be considered as means to prevent tumor metastasis to the brain.
Background
There are about 150,000 metastatic brain tumors diag-
nosed annually compared to 17,000 primary brain
tumors in the United States and the incidence of CNS
metastases is steadily increasing [1-4]. While advances in
cancer therapy have translated into longer survival for
patients with extraneural disease, these advances have,
ironically, increased the number of patients who develop
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CNS metastases. Despite decades of intensive investiga-
tion, and increasing success in treating extraneural cancer,
the median survival for patients with CNS metastases
from systemic cancer is only 6-10 months [5]. In patients
with CNS metastasis, neurologic disease is the primary
cause of disability in approximately half of the cases when
treated with whole brain radiation and a third of the cases
if treated with surgery and whole brain radiation [6].
Therefore, many patients experience significant disabili-
ties in the final weeks of life. CNS metastases are also an
important cause of disease relapse following high-dose
chemotherapy with bone marrow or stem cell support [7]
and a common reason for exclusion of patients from high-
dose chemotherapy protocols because of poor penetra-
tion of drugs into the CNS. For these reasons, strategies for
preventing CNS metastases and growth from systemic
cancer are vitally important.
Successful metastasis, depends on extracellular matrix
remodeling which in turn depends on proteolytic
enzymes [8]. Plasmin, a key component of the fibrinolytic
system is a promiscuous serine protease which directly
digests collagen, laminin, fibronectin, and proteoglycans
in the extracellular matrix and indirectly by activating
other matrixolytic enzymes (e.g. matrix metalloprotein-
ases). Plasmin is generated after activation of plasmino-
gen by urokinase- and tissue-type plasminogen activator
(uPA and tPA) [9,10]. uPA and tPA in turn can be inhib-
ited by the plasminogen activator inhibitors -1 and -2.
Melanoma is an excellent model to study the role of the
fibrinolytic system since it has a high propensity for brain
metastasis. Forty eight percent of patients with malignant
melanoma develop brain metastasis [11]. The central
nervous system appears to be a sanctuary for cancer cells
in patients being treated with most systemic cytotoxic
chemotherapies and immunotherapies. Consequently, as
the systemic therapy for metastatic melanoma improves,
CNS relapse is becoming more frequent and a major bar-
rier to long term survival. The median survival of patients
with melanoma metastatic to the central nervous system
is less than six months.
Methods
Cell culture
B16F10 mouse melanoma cells and SK-Mel human
melanoma cells were cultured in Dulbecco's modified
Eagle's medium (DMEM) and 10% fetal calf serum (FCS).
Human brain microvascular endothelial cells (BMEC)
were prepared as described previously [12]. The cells were
maintained in DMEM:Ham's F12 (1:1) containing 10%
FCS (Invitrogen, Carlsbad, CA) and 10% Nu serum (Bio-
Whittaker, Inc. Walkersville, MD).
Cell labeling
Radioactive labeling of B16F10 mouse melanoma cells
Half a million B16F10 cells were plated in 100 mm petri
dishes and left to grow for 48 hours in DMEM/F12 con-
taining 10% fetal calf serum. The medium was removed
and serum starved for 24 hours after which the medium
was exchanged and 10 ml of DMEM/F12 containing 1μCi
of  125  I-deoxyuridine (Perkin Elmer Boston, MA) was
added. The next day the medium was removed and the
cells washed with DMEM/F12 and used for further exper-
iments.
Labeling with Cell Tracker Orange™ (Molecular Probes, Eugene, 
OR)
Cells were plated in 100 mm ø petri dishes to reach con-
fluence. They were then washed with DMEM/F12 and 5
ml DMEM/F12 containing 10 μM Cell Tracker Orange™
and incubated for 40 min at 37°C in a 5% CO2 and 100%
humidity. Cells were washed with DMEM/F12 and incu-
bated for another 40 min. to allow the Cell Tracker
Orange™ to be incorporated.
In vitro blood-brain barrier model
To create an in vitro model of the human blood-brain bar-
rier (BBB), 50,000 human BMEC were seeded on top of
semipermeable Transwell™ polycarbonate tissue culture
inserts (pore size 8μm, 6.5 mm ø) (Corning Costar Corp.
Corning, NY). After 3 days the human BMEC formed a
continuous monolayer [13]. At this point the transend-
othelial electrical resistance (TEER) of this monolayer was
usually around 300-500 Ohm/cm2. The TEER was main-
tained at this level for the next 5-7 days. The TEER then
declined and soon thereafter cells appeared to detach
from the monolayer. For our experiments only monolay-
ers with TEER greater than 300 Ohm/cm2 were used.
Melanoma cell migration across BMEC
SK-Mel cells labeled with Cell Tracker Orange™, were
plated on the top of the BMEC monolayer in DMEM/F12.
As a chemo-attractant DMEM/F12 containing 10% FCS
was added to the bottom chamber. The next day the
inserts were examined for the presence and the location of
the cancer cells. The top site of the insert was cleaned with
a Q-tip swab and the remaining cells photographed and
counted. To ensure that these cells had crossed the BMEC
monolayer the bottom site of the insert was also cleaned
with a Q-tip. Cells that were not removed by the Q-tip
were not considered as having successfully crossed the
BMEC monolayer.
Animal tumor models
Plasminogen heterozygous mice in a C57Bl background
were a kind gift from Dr. Carmeliet (Vlaams Interuniversi-
tair Institut voor Biotechnologie, Leuven, Belgium) [14].
They were further backcrossed 6 times to commerciallyBMC Cancer 2006, 6:56 http://www.biomedcentral.com/1471-2407/6/56
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available C57Bl (Jackson Laboratories, Bar Harbor, ME)
and then intercrossed to generate wild type, heterozygous
and homozygous plasminogen deficient mice. Plasmino-
gen deficient mice have a limited lifespan (6-8 months)
and are not efficient breeders and the colony is main-
tained by crossing the heterozygous mice. For our experi-
ments 8-12 week old wild type and homozygous deficient
mice were used while the heterozygous mice were kept to
propagate the colony.
Intracarotid injection of tumor cells
To simulate hematogenous metastases to the brain we
employed an intracarotid tumor injection model in the
C57Bl mouse. Our intracarotid injection model is similar
to the one described by Schackert and Fidler [15]. Modifi-
cations include a) we used a 30 G needle to inject the cells
instead of a glass needle, and b) we sutured the site of
injection in the carotid artery to restore the blood circula-
tion. C57B mice were anesthetized with 50 mg/kg xyla-
zine 5 mg/kg ketamine cocktail. Mice were prepped with
betadine and all operation took place under the dissecting
microscope. A 1 cm incision in the neck was performed
and the left common carotid artery was exposed. The
external carotid artery was temporarily occluded with a 6-
0 prolene and the common carotid artery was temporarily
ligated with a microclip (George Tiemann, Hauppauge,
NY). A 30 G needle connected to PE-10 tubing (Becton
Dickinson, San Diego, CA) was inserted into the lumen of
the common carotid artery. The 5 μl cell suspension was
then injected and chased with 40 μl of Hanks balanced
salt solution over a period of 1 minute. Distal to the nee-
dle a microclip was placed and the needle removed. The
artery was sutured with a 10-0 prolene (Johnson & John-
son, Sommerville, NJ) and the microclips removed to re-
establish the blood flow. In most cases no bleeding was
observed but if there was some it could be stopped with
gentle pressure on the arteriotomy for 30-60 seconds.
Mice were returned to their cage with unlimited access to
food and water. More than 90% of the mice recovered
completely after the surgery and without any neurological
signs.
Intracranial injection of tumor cells
Anesthetized mice were placed in a stereotactic frame
Kopf (Tujunga CA) prepped with betadine and a 0.5 cm
incision was performed along the midline of the skull.
Two mm left of the bregma a burr hole was drilled and
tumor cells were injected 3 mm deep in the striatum over
the course of 5 min. Cells were resuspended in DMEM/
F12 at a concentration of 2 × 108/ml and 5 μl were
injected at a 1 μl per minute rate. After injection the nee-
dle was left in the striatum 5 min and then it was
removed. The skin was sutured and the animals returned
to their cage with unlimited access to food and water.
Results
Fate of intracarotid injected mouse melanoma cells
To determine the fate of the injected cells we labeled
B16F10 cells with 125I-deoxyuridine. 125I-deoxyuridine is
incorporated in the DNA of the B16F10 cells and is not
taken up by other mouse cells after injection [16]. It is
then secreted in the urine. As reported earlier [17] the
number of cells that remains in the brain rapidly decreases
after the injection over the course of hours to days. Only a
small percentage (0.69+/- 0.23%) was found in the brain
after 72 hours (Fig. 1A). These cells remained stable over
the course of ten days suggesting that the detected radio-
activity in the brain was from living cells that gave rise to
the subsequent tumors. The organs with the next highest
level of radioactivity were the lungs followed by the kid-
ney and the spleen. The levels of radioactivity in these
organs however, continued to decline over the course of
the next 10 days indicating that it represents dying cells.
This interpretation was further supported by the absence
of tumors in any of these organs two weeks after surgery.
The only tumors identified were in the brain. On occa-
sion, tumors were seen growing in the neck of these ani-
mals at the site of injection indicating that some cells had
either leaked during the procedure or adhered to the
carotid artery. Histologic examination of the hematoxy-
lin-eosin stained brain section from wild type mice indi-
cated that the cells were lodged in the blood vessels (Fig.
1B). From the blood circulation the cells extravasated into
the brain (Fig. 1B, C). Once there, the tumors started
growing into large masses (Fig. 1D) that often occupied
large areas of the brain frequently as much as 25% of the
brain volume depending on the time of incubation and
the number of cells injected.
Role of plasminogen in metastatic tumors to the brain
With the knowledge that we could reproducibly obtain
brain metastases in our intracarotid mouse model we then
set out to determine whether the fibrinolytic system plays
a role in the tumor metastasis to the brain. We injected
100,000 B16F10 cells in the carotid artery of wild type
mice and mice lacking plasminogen (plg-/-). After 14 days
all mice (wild type, and plg-/-) were sacrificed and the
brains removed and fixed in 4% paraformaldehyde over-
night. The brains were cut in 2 mm slices embedded in
paraffin and sections were obtained every 200 μm inter-
vals. Sections were stained with hematoxylin and eosin
and photographed with a SPOT camera mounted on a
Nikon E800 eclipse microscope. The tumor volume was
calculated by integrating the tumor area with the length of
the tumor. The tumor volume in plg-/- mice was 44.5%
smaller than the tumor volume found in the brains of
wild type mice (Fig. 2A). To ensure that the difference in
survival was not due to genetic abnormalities that
occurred with the genetic manipulations to generate the
knockout animals, wild type mice were also treated withBMC Cancer 2006, 6:56 http://www.biomedcentral.com/1471-2407/6/56
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the plasmin inhibitor ε-aminocaproic acid (EACA). Two
and a half percent of EACA was added in the water of the
mice two days prior to the operation and it was changed
daily. At this concentration the EACA levels in the blood
is 275-300 μg/ml that completely inhibits the conversion
of plasminogen to plasmin [18,19]. The tumor volume
was 42.4% smaller than the tumor seen in wild type mice
which would add support to our finding that plasmino-
gen most likely participate in tumor metastasis to the
brain of the plg-/- mice (Fig. 2A).
We then determined whether the reduction in tumor bur-
den translates into increased survival. In these experi-
ments the 12 wild type mice died, on average after 16.9+/
-1.6 days compared to the 11 plg-/- mice that died on aver-
age after 19.2+/-1.9 days. The 7 EACA treated wild type
mice also survived longer (18.8+/-1.3. days) than the
untreated wild type mice. Kaplan-Meyer analysis showed
these differences are statistically significant (log rank test,
p < 0.03) (Fig. 2B).
The observed differences in tumor size and mouse sur-
vival could be due to the effects of the fibrinolytic system
in tumor growth and/or the process of metastasis. We first
tested whether the fibrinolytic system affects tumor
growth directly in the brain by bypassing the blood-brain
barrier. We injected 100,000 B16F10 cells directly in the
striatum of wild type mice, wild type mice treated with
EACA and plg-/- mice. Twelve days after tumor cell implan-
tation the mice were sacrificed and the brains removed to
Metastatic brain tumor model Figure 1
Metastatic brain tumor model. A) One hundred thousand 125I-deoxyuridine-labeled B16F10 cells were injected in the left 
internal carotid artery. Mice were sacrificed after 1, 24, and 48 hours, 3 days and 7 days. The left hemisphere was removed and 
the amount of radioactivity was measured by means of the ICN gamma-counter to determine the number of cells remaining in 
the brain. Note the rapid decline of radioactivity in the brain that remained stable after 72 hours. Hematoxylin-eosin staining of 
melanoma tumors developing in the brain after intracarotid injection (B-D). B) B16F10 cells lodged in a blood vessel (arrow-
head) and cells invading the brain (arrow). C) B16F10 cells (arrow) growing in the brain parenchyma. D) Large tumor growing 
in the brain parenchyma (arrow).
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determine the volume of the growing tumors. No statisti-
cally significant difference in the size of these tumors was
observed (Fig. 3A).
To determine whether the difference in tumor volume was
due to the difference in the number of tumor cells metas-
tasizing to the brain we labeled B16F10 cells with125I-
iodo-2'-deoxyuridine and injected them into the internal
carotid artery. Seventy two hours after injection mice were
sacrificed, the brains removed and the radioactivity meas-
ured to determine the number of cells. Plasminogen defi-
cient (plg-/-) mice had 0.30%+/-0.1 of the initially injected
cells in the brain compared to 0.69% in wild type mice a
53.3+/-14.4% reduction (Fig. 3B). Similarly, EACA treated
mice contained 0.38%+/- 0.22 of the injected cells, 46.6%
fewer cells compared to untreated wild type mice. Taken
together these results suggest that the fibrinolytic system
in particular plasmin is important in the establishment of
the metastasis to the brain but not the growth of the
tumor in the brain once it gets there.
Melanoma cells crossing the blood-brain barrier model
To further understand the role of the fibrinolytic system in
tumor cell invasion of the brain we employed an in vitro
blood-brain barrier model formed by human brain micro-
vascular endothelial cells (BMEC) [12,20]. The BMEC are
positive for FVIII-Rag, carbonic anhydrase IV, Ulex
europeus agglutinin I and take up acetylated low-density
lipoprotein (AcLDL) demonstrating their endothelial ori-
gin and also express gamma glutamyl transpeptidase,
demonstrating their brain origin [12,20]. Brain endothe-
lial cells with these phenotypic expression were previously
immortalized by transfection with the SV40-large T-anti-
gen [20]. To determine whether tumor cells were able to
cross the blood-brain barrier model they were first labeled
with Cell Tracker Orange (Molecular Probes, Eugene,
OR). Human SK-Mel cells were placed on top of a monol-
ayer formed by BMEC in the presence or absence of plas-
minogen and the presence or absence of the plasminogen
inhibitor EACA and α2-antiplasmin. At the end of the
experiment the cells were photographed and counted. In
the absence of plasminogen virtually no cells crossed the
BBB model (0.56+/-0.3%). However, by adding human
plasminogen a 9-fold increase (5.32+/-0.78%) in the
number of cells crossing the BBB model was observed. By
adding the plasminogen inhibitor EACA or α2-antiplas-
min in addition to plasminogen we saw strong inhibition
of the plasminogen-dependent inhibition of tumor cell
Effect of plasminogen in tumor metastasis Figure 2
Effect of plasminogen in tumor metastasis. Metastatic brain tumors were established by injecting 106 B16F10 cells in the 
left internal carotid artery of wild type wild type C57Bl (wt), plasminogen deficient (plg-/-) and wild type mice treated with 
EACA (EACA). Fourteen days after tumor cell injection the mice were sacrificed the brains removed fixed and stained with 
hematoxylin eosin. The areas of the tumors at 200 μm intervals were measured and the total volume of the tumor determined. 
Note the reduced tumor size in mice treated with EACA and plg-/- mice compared to wild type mice. B) Survival graph of 12 
wild type mice (wt), 11 plg-/- mice (plg-/-) and 7 wild type mice treated with EACA (EACA) injected with 106 B16F10 cells. Note 
the increased survival of plg-/- and wild type mice treated with EACA compared to untreated wild type mice (p < 0.03)
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migration across the BBB (0.85+/-0.26% and 0.89+/-
0.32%, respectively) indicating that plasminogen is neces-
sary for crossing of the BBB model (Fig. 4).
Discussion
Since the first correlation between cancer and plasmino-
gen activation was drawn more than 25 years ago [21]
there has been more than 100 reports on the prognostic
value of uPA, tPA and the plasminogen activator inhibitor
-1 (PAI-1) (reviewed in [22-24]. Several studies on exper-
imental tumor models have been published suggesting
that inhibition of fibrinolytic enzymes can inhibit tumor
growth and metastasis [25-27]. EACA, a plasmin inhibi-
tor, reduced tumor growth by 37% in a xenograft tumor
model of glioma [18]. A synthetic inhibitor trans-4-amino
ethylcyclohexanecarbonyl-tyr-(O-Pic)-octylamide inhib-
ited human lung metastasis in a xenograft mouse model
[28]. Prostate carcinoma metastasis in a mouse model was
prevented by a synthetic urokinase inhibitor [29]. A study
using overexpression of uPA receptor in breast carcinoma
showed increased invasion and metastasis suggesting a
role of uPA in tumor growth [30]. Melanoma cells express
uPA and uPA receptor which may facilitate activation
plasmin [31]. In a survey of skin cancers the levels of uPA
correlated with the malignancy of the tumors with malig-
nant melanoma containing the highest amounts of uPA,
followed by squamous cell carcinoma and basal cell carci-
noma containing the least amount of uPA [32]. Inhibition
of plasminogen and plasminogen activators reduced
melanoma cell migration in an in vitro model [33].
Melanoma cells transfected with plasminogen activation
inhibitor-1 developed fewer metastases than not trans-
fected cells in a lung metastasis model [34] and in an ocu-
lar melanoma tumor model [35].
Brain metastases from systemic cancers are increasing
despite advances in systemic treatments. In an attempt to
dissect the underlying mechanisms for brain metastases
we injected melanoma tumor cells directly into the
carotid arteries of mice to establish a model for hematog-
enous metastases to the CNS. By manipulating the pres-
ence or absence of plasminogen with plasminogen
knockout mice we demonstrated that in the absence of the
expression of plasminogen the metastatic tumors were
smaller and the survival of the corresponding mice were
significantly longer. When we pretreated the wild type
Plasminogen facilitates the process of metastasis but not tumor growth in the brain Figure 3
Plasminogen facilitates the process of metastasis but not tumor growth in the brain. A) Ten thousand B16F10 cells 
were injected in the striatum of 5   wild-type mice (control), 5 plg-/- mice (plg-/-) and 5 wild type mice   treated with EACA 
(EACA). The mice were sacrificed 12 days after tumor   cell injection and the brains removed to determine the size of the   
growing tumor (bars show the standard deviation). No statistically   significant difference between the three groups was 
observed. B)   Wild-type mice (wt),plg-/- mice and wild type mice treated with EACA   (EACA) were injected with 100,000 
125I-deoxyuridine labeled B16F10   cells in the internal carotid artery. They were sacrificed 3 days later   and their brains 
removed to determine the amount of radioactivity and   compared to the total amount radioactivity injected in these mice. The   
bars represent the average of six mice for each group (bars show the   standard deviation). The amount of radioactivity found 
in the wild type   mice was considered as 100% *p<0.01.
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mice with EACA, a plasminogen inhibitor, prior to intrac-
arotid injection of melanoma cells the brain metastases
were also smaller and these animals survived longer simi-
lar to the plasminogen knockout mice. The smaller
tumors in the EACA treated and plasminogen knockout
mice could be due to inhibition of tumor growth in the
brain once the melanoma cells reached there or inhibition
of tumor cells moving across the blood-brain barrier. Our
experiments with direct brain injections of tumor cells in
the plasminogen knockout mice and EACA treated wild
type mice showed no reduction of tumor size compared to
the tumors in wild type mice. These results would suggest
that plasmin is important in the migration of tumor cells
across the blood-brain barrier into the brain parenchyma
and not in the growth of the tumor once it is established
in the brain. Plasmin can modulate cell adhesion by
directly digesting tenascin as it has been shown in lym-
phocytes [36]. It can promote cell motility by regulating
the interaction between vitronectin and uPA [37]. It can
facilitate cell migration across the blood-brain barrier by
directly digesting fibronectin and laminin [38,39]. In the
brain parenchyma plasmin can interact and digest the L1-
cell adhesion molecules to disrupt cell adhesion [40]. In
addition, to these direct effects, plasmin activates matrix
metalloproteinases that in turn digest other extracellular
matrix proteins or modulate gene expression of other
genes [41]. To determine whether migration of tumor
cells across the BBB is dependent on plasmin we utilized
an in vitro BBB model using human brain microvascular
endothelial cells (BMEC). These experiments demon-
strated that the migration of human melanoma cells
across the BMEC was dependent on plasmin. With inhibi-
tion of plasmin significantly fewer melanoma cells cross
the BMEC. However, these in vitro studies do not take into
account the possibility that tumor cells can simply get
lodged in the capillaries and start proliferating there.
Once they reach a critical mass the capillaries may simply
break allowing the cells to enter the brain parenchyma.
Conclusion
Our experiments suggest that the fibrinolytic system is
involved in facilitating melanoma cells cross of the blood-
brain barrier, but the minimal increase in animal survival,
suggests that other enzymes may be involved. Studies sug-
gest that matrix metalloproteinases (MMPs) and a disin-
tegrin and metalloproteinase family of proteolytic
enzymes (ADAMTS) may also play a role in the develop-
ment of metastases [42,43]. In fact, inhibition of matrix
metalloproteinases, leads to restoration of the blood-
brain barrier in an experimental autoimmune encephalo-
myelitis [44]. Further understanding of the mechanisms
by which systemic cancers metastasize to the brain will
enable us to devise novel methods to inhibit brain metas-
tasis across the blood-brain barrier and improved survival
for patients.
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Cancer cell transversal of the in vitro blood-brain barrier  model Figure 4
Cancer cell transversal of the in vitro blood-brain 
barrier model. 50,000 BMEC were plated on 6.5 mm ø 
transwells coated with collagen and 8.0 μm pore size in 
DMEM/F12/10%FCS/10%Nu serum. After 3 days the cells 
had grown to confluence and the medium was removed and 
replaced with DMEM/F12. After two more days 10,000 
human SK-melanoma cells (SK-Mel) labeled with Cell-
Tracker Orange™ were added. These co-cultures were fur-
ther incubated in the absence of exogenous plasminogen 
(control), in the presence of 1 μg/ml plasminogen (plg) and in 
the presence of plasminogen and EACA (EACA). The results 
are the average of three experiments performed in duplicate. 
Error bars show standard deviation. *p < 0.01.
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